Dr. Reddy's Laboratories (NYSE:RDY) Shares Gap Up - Time to Buy?

Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $12.68, but opened at $13.20. Dr. Reddy's Laboratories shares last traded at $13.19, with a volume of 99,105 shares trading hands.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Nomura cut shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research note on Thursday, December 19th. StockNews.com downgraded Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a report on Friday, December 6th.

Dr. Reddy's Laboratories Trading Up 1.1 %

The company's 50-day moving average is $13.69 and its 200-day moving average is $14.73. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The firm has a market cap of $11.46 billion, a price-to-earnings ratio of 21.86 and a beta of 0.48.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, research analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current year.

Remove Ads

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Dr. Reddy's Laboratories during the fourth quarter valued at $206,000. NorthCrest Asset Manangement LLC raised its holdings in Dr. Reddy's Laboratories by 395.9% during the 4th quarter. NorthCrest Asset Manangement LLC now owns 55,025 shares of the company's stock worth $869,000 after purchasing an additional 43,930 shares during the last quarter. Pinnacle Wealth Planning Services Inc. lifted its position in Dr. Reddy's Laboratories by 203.4% during the 4th quarter. Pinnacle Wealth Planning Services Inc. now owns 26,744 shares of the company's stock valued at $422,000 after purchasing an additional 17,930 shares during the period. B. Riley Wealth Advisors Inc. boosted its stake in shares of Dr. Reddy's Laboratories by 829.5% in the 4th quarter. B. Riley Wealth Advisors Inc. now owns 57,350 shares of the company's stock valued at $906,000 after purchasing an additional 51,180 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Dr. Reddy's Laboratories by 100.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 16,511 shares of the company's stock worth $261,000 after buying an additional 8,262 shares during the period. 3.85% of the stock is currently owned by institutional investors.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.